Work

Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection

Year: 2024

Type: letter

Abstract: We thank Dr. Sun and colleagues for their timely, clinically relevant perspective on how dynamic access to pharmacogenomic testing results is critical to ensure this new knowledge can optimize the potential to inform clinical decision making. There is agreement that for clinical decision support tools to have maximal utility, electronic health record (EHR) functionality must focus on an electronic interface, ideally not an electronic file, which facilitates easy access to the data beyond the ordering clinician and allows for updates of new pharmacogenomic variants and antidepressants. Hard copy paper reports loaded into a media section or static laboratory reports without capacity to add new knowledge will quickly become non-current and likely lost in the EHR.

Source: Neuropsychopharmacology

DOI: 10.1038/s41386-024-01815-4

Authors: Mark A. Frye, Charles B. Nemeroff

Institutions: Mayo Clinic, The University of Texas at Austin

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,990